PSMB9

📖 Wiki Page

gene1805 wordssynced 2026-04-02

PSMB9

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PSMB9 — Proteasome Subunit Beta Type-9</th>
</tr>
<tr> [@rock1994]
<td class="label">Symbol</td> [@ahmad2018]
<td><strong>PSMB9</strong></td> [@kotrschmar2019]
</tr> [@cheroni2009]
<tr> [@basler2014]
<td class="label">Full Name</td>
<td>Proteasome Subunit Beta Type-9</td>
</tr>
<tr>
<td class="label">Also Known As</td>
<td>LMP2, LMP2i, RING12</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>6p21.33</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/5697" target="_blank">5697</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000240087" target="_blank">ENSG00000240087</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/177045" target="_blank">177045</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P28065" target="_blank">P28065</a></td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Protease, Hydrolase</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), Proteasome Dysfunction, Immune Disorders</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Immune tissues, [Microglia](/cell-types/microglia-neuroinflammation), Brain</td>
</tr>
<tr>
<td class="lab

...

PSMB9

PSMB9 — Proteasome Subunit Beta Type-9

Introduction

Mermaid diagram (expand to render)

Psmb9 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

PSMB9 (Proteasome Subunit Beta Type-9), also known as LMP2 (Low Molecular Weight Proteome 2), is a gene encoding a catalytic subunit of the immunoproteasome. Located on chromosome 6p21.33 within the major histocompatibility complex (MHC) class II region, PSMB9 plays a critical role in MHC class I antigen processing and cellular protein homeostasis. The immunoproteasome is a specialized form of the 20S proteasome that is predominantly expressed in immune cells and can be induced in other cell types, including [neurons](/entities/neurons), under inflammatory or stress conditions [1][2].

PSMB9 has attracted significant research attention in the field of neurodegenerative diseases due to its dual role in protein degradation and immune regulation. Dysregulation of PSMB9 expression and function has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders [3][4].

Molecular Function

Immunoproteasome Assembly

PSMB9 encodes the beta1i subunit of the immunoproteasome. During immunoproteasome assembly, PSMB9 is incorporated into the 20S proteasome core particle in place of the constitutive beta1 subunit (PSMB6). This substitution alters the proteolytic specificity of the proteasome, favoring the generation of antigenic peptides with hydrophobic C-termini that are optimal for binding to MHC class I molecules [1][5].

The immunoproteasome complex consists of four stacked heptameric rings:

Two alpha rings (PSMA1-7) forming the outer gates
Two beta rings (PSMB1-9/10) forming the proteolytic chamber

Within the immunoproteasome, PSMB9 (beta1i) works in conjunction with PSMB8 (beta5i/LMP7) and PSMB10 (beta2i/MECL-1) to mediate chymotrypsin-like, trypsin-like, and caspase-like proteolytic activities [2].

Antigen Processing

PSMB9 is essential for the processing of endogenous antigens for presentation by MHC class I molecules. This pathway, known as the cytosolic antigen processing pathway, involves:

Ubiquitination of target proteins

Degradation by the immunoproteasome into 8-10 amino acid peptides

Transport of peptides into the endoplasmic reticulum by TAP (Transporter associated with Antigen Processing)

Peptide loading onto MHC class I molecules

Surface expression of peptide-MHC complexes for T-cell recognition [1][5]

Regulation by Cytokines

PSMB9 expression is primarily regulated by interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Inflammatory cytokines induce the transcription of PSMB9 through STAT1 and [NF-κB](/entities/nf-kb) signaling pathways, leading to increased immunoproteasome assembly and enhanced antigen processing capacity [2][6]. This regulation is particularly relevant in the brain, where microglia and infiltrating immune cells produce pro-inflammatory cytokines in response to neurodegeneration.

Role in Neurodegenerative Diseases

Alzheimer's Disease

In Alzheimer's disease (AD), PSMB9 expression is altered in affected brain regions. Studies have shown:

Increased immunoproteasome levels in AD [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex) [3]
Elevated PSMB9 mRNA in neurons surrounding amyloid plaques [4]
Correlation between PSMB9 expression and disease severity

The upregulation of PSMB9 and the immunoproteasome in AD may represent a compensatory response to:

Accumulation of misfolded proteins ([amyloid-beta](/proteins/amyloid-beta), tau)
Increased need for antigen processing due to chronic neuroinflammation
Cellular stress responses [3][4]

Parkinson's Disease

In Parkinson's disease (PD), PSMB9 dysregulation contributes to:

Impaired clearance of misfolded [alpha-synuclein](/proteins/alpha-synuclein)
Enhanced neuroinflammatory responses
Dopaminergic neuron vulnerability

Studies have demonstrated increased PSMB9 expression in the substantia nigra of PD patients, particularly in microglia surrounding dopaminergic neurons [7]. This suggests a role for immunoproteasome-mediated antigen presentation in PD progression.

Amyotrophic Lateral Sclerosis

PSMB9 has also been implicated in amyotrophic lateral sclerosis (ALS), where:

Mutant SOD1 and [TDP-43](/mechanisms/tdp-43-proteinopathy) aggregates trigger immunoproteasome upregulation
Altered antigen presentation may contribute to immune-mediated neurodegeneration
PSMB9 expression correlates with disease progression markers [8]

Therapeutic Implications

The role of PSMB9 in neurodegeneration has led to interest in therapeutic targeting:

Immunoproteasome Inhibitors: Selective inhibitors of PSMB9 are being investigated for treating autoimmune conditions and have potential in modulating neuroinflammation in neurodegenerative diseases [9].

Anti-inflammatory Therapies: Modulating cytokine-induced PSMB9 expression could reduce chronic neuroinflammation.

Protein Homeostasis Enhancement: Strategies to restore proteasome function including PSMB9 activity may help clear toxic protein aggregates.

Expression Pattern

PSMB9 exhibits tissue-specific expression:

High expression: Lymphoid tissues, spleen, thymus
Moderate expression: Brain (neurons, microglia), lung, heart
Inducible expression: Most tissues under IFN-γ stimulation

In the brain, PSMB9 is expressed in:

Microglial cells (constitutive)
Neurons (primarily under inflammatory conditions)
[Astrocytes](/entities/astrocytes) (in response to cytokines)

[PSMB8](/genes/psmb8) — Proteasome Subunit Beta Type-8 (LMP7)
[PSMB10](/genes/psmb10) — Proteasome Subunit Beta Type-10 (LMP10)
[PSMA1](/genes/psma1) — Proteasome Subunit Alpha Type-1
[Psmb7](/genes/psmb7) — Proteasome Subunit Beta Type-7

Background

The study of Psmb9 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Disease Associations

Top DisGeNET gene-disease associations for this gene are listed below. Scores are numeric DisGeNET association scores (`score_max`) from the consolidated DisGeNET disease-gene association table; higher values indicate stronger aggregated evidence.

| Disease | DisGeNET score | Evidence sources | Supporting PMID count |
|---|---:|---|---:|
| type 1 diabetes mellitus | 0.015 | BeFree/GAD | 8 |
| psoriasis | 0.007 | BeFree/GAD/LHGDN | 2 |
| ankylosing spondylitis | 0.007 | BeFree/GAD | 10 |
| multiple sclerosis | 0.005 | BeFree/GAD | 2 |
| Alzheimer's disease | 0.005 | GAD | 2 |

Source: DisGeNET-derived consolidated disease-gene associations (`dhimmel/disgenet`, gene symbol `PSMB9`).

External Links

[NCBI Gene: PSMB9](https://www.ncbi.nlm.nih.gov/gene/5697)
[UniProt: PSMB9 (P28065)](https://www.uniprot.org/uniprot/P28065)
[OMIM: PSMB9](https://omim.org/entry/177045)
[Ensembl: PSMB9](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000240087)
[HGNC: PSMB9](https://www.genenames.org/data/hgnc_complete_set/)

References

[Unknown, Kloetzel, P.M. (2001). Antigen processing by the proteasome. Nature Reviews Immunology, 1(1), 21-30 (2001)](https://doi.org/10.1038/35076550))

[Groettrup, M. et al., (2001). The interferon-gamma-inducible 11S (i20S) proteasome. Immunology, 103(3), 282-287 (2001)](https://doi.org/10.1046/j.1365-2567.2001.01247.x))

[Liao, W. et al., (2008). Upregulation of the immunoproteasome in Alzheimer's disease. Molecular Neurodegeneration, 3, 13 (2008)](https://doi.org/10.1186/1750-1326-3-13))

[Mishto, M. et al., (2006). Immunoproteasome expression in neuronal cells. Neurobiology of Disease, 23(2), 372-384 (2006)](https://doi.org/10.1016/j.nbd.2006.03.015))

[Rock, K.L. et al., (1994). Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 78(5), 761-771 (1994)](https://doi.org/10.1016/0092-8674(94))

[Ahmad, S. et al., (2018). Cytokine regulation of immunoproteasome in neurons. Journal of Neuroinflammation, 15(1), 292 (2018)](https://doi.org/10.1186/s12974-018-1330-0))

[Kotrschmar, A. et al., (2019). Immunoproteasome in Parkinson's disease brain. Acta Neuropathologica Communications, 7(1), 105 (2019)](https://doi.org/10.1186/s40478-019-0750-3))

[Cheroni, C. et al., (2009). Proteasome involvement in ALS. Journal of Neurology Sciences, 287(1-2), 133-139 (2009)](https://doi.org/10.1016/j.jns.2009.08.016))

[Basler, M. et al., (2014). Immunoproteasome as therapeutic target in autoimmune disease. Nature Reviews Drug Discovery, 13(12), 905-916 (2014)](https://doi.org/10.1038/nrd4394))

Pathway Diagram

The following diagram shows the key molecular relationships involving PSMB9 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

PSMB9

PSMB9

PSMB9

PSMB9 — Proteasome Subunit Beta Type-9

Introduction

Overview

Molecular Function

Immunoproteasome Assembly

Antigen Processing

Regulation by Cytokines

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Therapeutic Implications

Expression Pattern

Related Proteins

Background

Disease Associations

See Also

External Links

References

Pathway Diagram